189 related articles for article (PubMed ID: 28301274)
1. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.
Zheng X; Rong X; Feng Y; Sun X; Li L; Wang Q; Wang M; Liu W; Li C; Yang Y; Zhou R; Lu J; Feng L; Chen L
Emerg Microbes Infect; 2017 Jun; 6(6):e43. PubMed ID: 28588291
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
Zhao H; Xu C; Luo X; Wei F; Wang N; Shi H; Ren X
Front Immunol; 2018; 9():335. PubMed ID: 29563911
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China.
Yu B; Zhou Y; Wu H; Wang Z; Zhan Y; Feng X; Geng R; Wu Y; Kong W; Yu X
J Med Virol; 2012 Sep; 84(9):1408-14. PubMed ID: 22825819
[TBL] [Abstract][Full Text] [Related]
9. A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China.
Liu Q; Huang W; Nie J; Zhu R; Gao D; Song A; Meng S; Xu X; Wang Y
PLoS One; 2012; 7(3):e33392. PubMed ID: 22438922
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China.
Sun C; Zhang Y; Feng L; Pan W; Zhang M; Hong Z; Ma X; Chen X; Chen L
Vaccine; 2011 May; 29(22):3837-41. PubMed ID: 21447314
[TBL] [Abstract][Full Text] [Related]
11. A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.
Yu B; Wang Z; Dong J; Wang C; Gu L; Sun C; Kong W; Yu X
Virol J; 2012 Nov; 9():287. PubMed ID: 23176136
[TBL] [Abstract][Full Text] [Related]
12. Seroprevalence of Human Adenovirus Type 5 Neutralizing Antibody in Common Marmosets Determined by a New Set of Two Assays.
Wang Q; Sun Y; Xu Y; Wang Y; Wang H; Fu Y; Allain JP; Li C; Li T
Viral Immunol; 2019 Oct; 32(8):348-354. PubMed ID: 31433272
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China.
Yi H; Wang Q; Deng J; Li H; Zhang Y; Chen Z; Ji T; Liu W; Zheng X; Ma Q; Sun X; Zhang Y; Yu X; He M; Chen L; Feng Y
Virol Sin; 2022 Oct; 37(5):716-723. PubMed ID: 35764207
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.
Jian L; Zhao Q; Zhang S; Huang W; Xiong Y; Zhou X; Jia B
Arch Virol; 2014 Mar; 159(3):465-70. PubMed ID: 24057756
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines.
Pilankatta R; Chawla T; Khanna N; Swaminathan S
J Med Virol; 2010 Mar; 82(3):407-14. PubMed ID: 20087930
[TBL] [Abstract][Full Text] [Related]
17. Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon.
Su X; Tian X; Jiang Z; Ma Q; Liu Q; Lu X; Zhou R
PLoS One; 2016; 11(6):e0156984. PubMed ID: 27328032
[TBL] [Abstract][Full Text] [Related]
18. Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa.
Wang B; Li J; Wu S; Chen Y; Zhang Z; Zhai Y; Guo Q; Zhang J; Song X; Zhao Z; Hou L; Chen W
Emerg Microbes Infect; 2018 Dec; 7(1):200. PubMed ID: 30514848
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Pre-Existing Neutralizing Antibody to Human Adenovirus Types 5 and 49 and Simian Type 23 in Chinese Population.
Zou P; Wang Q; Zhang P; Luo S; Wang C; Zhang E; Zhang L; Li C; Li T
Viral Immunol; 2023 Nov; 36(9):617-625. PubMed ID: 37903228
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
Zhang S; Huang W; Zhou X; Zhao Q; Wang Q; Jia B
J Med Virol; 2013 Jun; 85(6):1077-84. PubMed ID: 23588735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
